Le Lézard
Classified in: Science and technology
Subjects: CCA, ACC, FVT

Eltek Sets Earnings Release Date and Conference Call to Report Third Quarter 2019 Results on November 20, 2019

PETACH-TIKVA, Israel, Nov. 13, 2019 /PRNewswire/ -- Eltek Ltd. (NasdaqCM: ELTK), a global manufacturer and supplier of technologically advanced solutions in the field of printed circuit boards, announced today that it will release its financial results for the third quarter of 2019 on Wednesday, November 20, 2019, before the market opens. Eltek's financial results will be released over the news wires and will be posted on its corporate website at: www.nisteceltek.com.


Eltek Logo


On Wednesday, November 20, 2019, at 8:30 a.m. Eastern Time, Eltek will conduct a conference call to discuss the results. The call will feature remarks by Eli Yaffe, Chief Executive Officer and Alon Mualem, Chief Financial Officer.

To participate, please call the following teleconference numbers. Please allow for additional time to connect prior to the call:

United States:      +1-888-668-9141

Israel:                  +972-3-918-0609

International:        +972-3-918-0609

           8:30 a.m. Eastern Time
           5:30 a.m. Pacific Time
           15:30 p.m. Israel Time

A replay of the call will be available through the Investor Info section on Eltek's corporate website at http://www.nisteceltek.com approximately 24 hours after the conference call is completed and will be archived for 30 days.

About Eltek

Eltek ? "Innovation Across the Board", is a global manufacturer and supplier of technologically advanced solutions in the field of printed circuit boards (PCBs), and is the Israeli leader in this industry. PCBs are the core circuitry of most electronic devices. Eltek specializes in the manufacture and supply of complex and high quality PCBs, HDI, multilayered and flex-rigid boards for the high-end market. Eltek is ITAR compliant and has AS-9100 and NADCAP Electronics certifications. Its customers include leading companies in the defense, aerospace and medical industries in Israel, the United States, Europe and Asia.

Eltek was founded in 1970. The Company's headquarters, R&D, production and marketing center are located in Israel. Eltek also operates through its subsidiaries in North America and in Europe and by agents and distributors in Europe, India, South Africa and South America.

For more information, visit Eltek's web site at www.nisteceltek.com.

Forward Looking Statement

Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to statements regarding expected results in future quarters, risks in product and technology development and rapid technological change, product demand, the impact of competitive products and pricing, market acceptance, the sales cycle, changing economic conditions and other risk factors detailed in the Company's Annual Report on Form 20-F and other filings with the United States Securities and Exchange Commission.

Investor Contact:
Alon Mualem
Chief Financial Officer

SOURCE Eltek Ltd.

These press releases may also interest you

at 07:05
PharmaCyte Biotech, Inc. , a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the...

at 07:05
Cubic Corporation today announced its Cubic Transportation Systems (CTS) business division published an industry-guiding white paper titled, "Leveraging Technology to Adapt and Thrive Post-Pandemic." The white paper discusses how the latest...

at 07:05
The global design agencies is poised to experience spend growth of more than USD 31 billion between 2019-2024 at a CAGR of over 7.81%. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Request free...

at 07:05
The leading Robotic Process Automation (RPA) company, UiPath, today announced it has closed its Series E investment round, raising $225 million at a post-money valuation of $10.2 billion. The round was led by Alkeon. Others participating include...

at 07:05
Dewpoint Therapeutics, the biomolecular condensates company, announced today that it has forged an exclusive collaboration agreement with Merck, known as MSD outside the United States and Canada, to apply Dewpoint's proprietary platform for...

at 07:05
Rocket Pharmaceuticals, Inc. ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the first patient has received investigational therapy in the...

News published on 13 november 2019 at 08:00 and distributed by: